Pharmaceutical composition for oral administration, for treatment of liver cancer
The present invention relates to a pharmaceutical composition for oral administration, for treatment of liver cancer, comprising a benzothiazole aniline derivative. The pharmaceutical composition, when orally administered, exhibits a therapeutic effect on liver cancer, in particular, an excellent effect of reducing the tumor size of liver cancer, while toxicity is significantly attenuated.
1 . A method for treating liver cancer, the method comprising:
orally administering to a subject in need of liver cancer treatment a compound represented by a following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
wherein in the Chemical Formula 1,
X 1 represents NH, O or S,
L represents
A represents a following Chemical Formula A-1:
2 . The method of claim 1 , wherein in the Chemical Formula 1, X 1 represents S, and L represents
3 . The method of claim 1 , wherein the compound represented by the Chemical Formula 1 is a compound represented by a following Chemical Formula 1-1:
4 . The method of claim 1 , wherein the compound represented by the Chemical Formula 1 or the pharmaceutically acceptable salt thereof is part of a pharmaceutical composition.
5 . The method of claim 4 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
6 . The method of claim 5 , wherein the pharmaceutically acceptable carrier includes an excipient or a diluent.
7 . The method of claim 6 , wherein the excipient comprises one or more of starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose or magnesium stearate.
8 . The method of claim 4 , wherein the pharmaceutical composition is in a form of a liquid formulation.
9 . The method of claim 1 , further comprising identifying the subject in need of treatment of the liver cancer before the oral administration step.
10 . The method of claim 1 , wherein the subject in need of liver cancer treatment is a human.
11 . The method of claim 1 , wherein the compound represented by the Chemical Formula 1 or the pharmaceutically acceptable salt thereof is administered in an amount of 0.005 to 100 mg/kg of body weight of the subject.